SCHEDULE: Vincent LoPriore Discloses 21.46% Stake in Hepion Pharma

Executive Chairman Vincent LoPriore and affiliated entities report a combined 21.46% beneficial ownership stake in Hepion Pharmaceuticals, Inc.

Summary

• Vincent LoPriore, Executive Chairman of Hepion Pharmaceuticals, has filed a Schedule 13D disclosing a total beneficial ownership of 6,250,000 shares.
• The stake represents 21.46% of the company's 29,119,317 outstanding common shares as of April 21, 2026.
• Holdings are split between Gravitas Capital LP (5,000,000 shares) and the Invictus Capital Advisors Pension Plan (1,250,000 shares).
• The aggregate purchase price for the reported shares was approximately $250,000.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects strong insider commitment, though it does not provide new information regarding the company's clinical or operational progress.

Positives

• Demonstrates significant insider alignment and confidence from the Executive Chairman.
• Consolidation of voting power among entities controlled by a key executive.

Negatives

• The relatively low aggregate purchase price of $250,000 for 6.25 million shares suggests a very low cost basis, potentially indicating historical accumulation or specific transaction pricing.

Risks

• Concentration of ownership may influence corporate decision-making.
• Potential for future market volatility if the reporting person decides to adjust their position.

Future Outlook

The reporting persons state the shares were acquired for investment purposes and may make further acquisitions of common stock from time to time.

Management Comments

• The Reporting Persons have no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D, other than potential future acquisitions.

Industry Context

StockSavvy.ai notes that significant insider accumulation in small-cap biotech firms often signals management's belief in the underlying clinical pipeline or potential strategic value, though it can also reflect efforts to stabilize share price during periods of volatility.

Comparison to Industry Standards

• Insider ownership levels exceeding 20% are considered high for a publicly traded company, indicating strong control and alignment.
• The filing follows standard regulatory requirements for beneficial ownership disclosure under the Securities Exchange Act of 1934.

Legal Proceedings

• None disclosed.

Related Party Transactions

• Vincent LoPriore serves as Executive Chairman of the Issuer and is the Managing Member of Gravitas Capital LP and trustee of the Pension Plan.

Stakeholder Impact

• Increased concentration of voting power may impact future shareholder votes.
• Signals to the market that leadership maintains a significant financial interest in the company's success.

Next Steps

• Potential further acquisitions of common stock by the reporting persons.

Key Dates

Recommendation

The filing confirms significant insider ownership, which is generally a positive signal for long-term alignment, but does not change the fundamental investment thesis regarding the company's clinical pipeline or financial performance.

Keywords

Hepion Pharmaceuticals, Schedule 13D, Vincent LoPriore, Insider Ownership, Biotech, Equity Stake